← FDA DRUG APPROVALS

FDA ANDA · ANDA210441

HYDROXYCHLOROQUINE SULFATE

Sponsor: APPCO

APPLICATION
ANDA210441
TYPE
ANDA
ORIGINAL APPROVAL
2018-05-01
LATEST ACTION
2024-10-08
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

HYDROXYCHLOROQUINE SULFATEPrescription
HYDROXYCHLOROQUINE SULFATE 400MG · TABLET · ORAL
HYDROXYCHLOROQUINE SULFATEPrescription
HYDROXYCHLOROQUINE SULFATE 100MG · TABLET · ORAL
HYDROXYCHLOROQUINE SULFATEPrescription
HYDROXYCHLOROQUINE SULFATE 300MG · TABLET · ORAL
HYDROXYCHLOROQUINE SULFATEPrescription
HYDROXYCHLOROQUINE SULFATE 200MG · TABLET · ORAL

Approval history

2024-10-08Labeling · Supplement 15 · standardAP
2023-11-29Labeling · Supplement 13 · standardAP
2022-09-19Manufacturing (CMC) · Supplement 10 · unknownAP
2022-07-07Labeling · Supplement 12 · standardAP
2022-04-27Labeling · Supplement 8 · standardAP
2018-05-01UNKNOWN · Original · standardLabelAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →